抗巨细胞病毒感染新药Letermovir研究进展  

Research progress on the new drug of anti-cytomegalovirus infection:letermovir

作　　者：李艳娇[1] 曲晓宇[1] 赵浩荻 宋燕青[1] LI Yan-jiao;QU Xiao-yu;ZHAO Hao-di;SONG Yan-qing(Department of Pharmacy,the First Hospital of Jilin University,Changchun 130021,China;College of Pharmacy,Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院药学部,长春130021 [2]吉林大学药学院,长春130021

出　　处：《实用药物与临床》2018年第11期1304-1308,共5页Practical Pharmacy and Clinical Remedies

摘　　要：巨细胞病毒(Cytomegalovirus,CMV)感染在人群中很常见,在临床上通常表现轻微或无症状,但是在严重免疫功能低下的个体中,其可侵袭多个器官和系统,产生严重后果,甚至危及生命。Letermovir是一种新型非核苷类巨细胞病毒抑制剂,目前批准适应证为CMV感染和成人异基因造血干细胞移植(Hematopoietic stem cell transplantation,HSCT) CMV阳性者。本文对其药动学、药效学、药物相互作用、临床前研究、临床研究、不良反应等方面进行综述。Cytomegalovirus（ CMV） infection is common in people,which often presents mildly or asymptomatically. But in individuals with severe immunodeficiency,many organs and systems can be attacked,resulting in serious diseases and even endangering life. Letermovir is a newtype of non-nucleoside cytomegalovirus inhibitor,which is currently indicated for CM V infection and disease in adult cytomegalovirus seropositive recipients of an allogeneic hematopoietic stem cell transplantation（ HSCT）. This article makes a summary of the pharmacokinetics,pharmacodynamics,drugs interaction,preclinical study,clinical study and adverse effects of letermovir.

关 键 词：乐特莫韦 巨细胞病毒 感染 

分 类 号：R978.7[医药卫生—药品]